REG - Tissue Regenix Group - Secondary Trading Following Cancellation

Tissue RegenixAnnouncement

07/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260107:nRSG8757Na&default-theme=true

RNS Number : 8757N  Tissue Regenix Group PLC  07 January 2026

 

Tissue Regenix Group plc

('Tissue Regenix', the 'Group', or the 'Company')

 

Secondary Trading Following Cancellation

 

Tissue Regenix Group plc, the regenerative medical devices company,
announces details of the secondary market trading facility that will be in
place following the cancellation of the admission to trading on AIM of its
ordinary shares ("Cancellation").

 

As previously announced, following approval by shareholders at the General
Meeting held on 22 December 2025, the Cancellation will take effect from 7.00
a.m. on 7 January 2026.

 

Following the Cancellation, the Company has appointed Asset Match to
facilitate trading in the Ordinary Shares. Asset Match, a firm authorised and
regulated by the Financial Conduct Authority ((FRN 579310), will operate an
electronic off-market dealing facility for the Ordinary Shares. This facility
will allow existing holders of ordinary shares in the Company ("Shareholders")
and new investors to trade ordinary shares by matching buyers and sellers
through periodic auctions.

 

New investors and existing Shareholders are encouraged to register
on www.assetmatch.com (http://www.assetmatch.com/)  and add Tissue Regenix
to their 'Watchlist' to continue to receive Company updates and auction/price
information. Please note the Tissue Regenix page will go live on Asset Match
on 7 January 2026.

 

The Asset Match trading facility operates under its own code of practice which
governs the behaviour of participants and the running of the periodic
auctions. Asset Match operates an open auction system where volumes of bids
and offers at different prices are displayed on its website together with the
closing date of the auction. At the end of each auction period, Asset Match
passes this information through a non-discretionary algorithm that determines
a "market-derived" share price based on supply and demand and allocates
transactions accordingly. Bids and offers may be made and withdrawn at any
time before the closing date of each auction.

 

Shareholders will continue to be able to hold their shares in uncertificated
form (i.e. in CREST) and should check with their existing stockbroker whether
they are willing or able to trade in unquoted shares. Shareholders wishing to
trade shares through Asset Match must do so through a stockbroker. A
comprehensive list of stockbrokers who have signed up to access the Asset
Match platform is available on request by emailing dealing@assetmatch.com.

 

Full details will be made available to Shareholders on the Company's website
at www.tissueregenix.com (http://www.tissueregenix.com/) and directly by
letter or e-mail (where appropriate). Shareholders may contact Asset Match in
relation to any queries regarding trading via the secondary market trading
facility by emailing dealing@assetmatch.com.

 

For more information, please contact:

 

 Tissue Regenix Group plc
 Jay LeCoque, Executive Chairman                                                   via Walbrook PR

 Asset Match Limited                                               +44(0) 207 248 2788

 Walbrook PR (Financial PR and IR)  Tel: +44 (0)20 7933 8780 or TissueRegenix@walbrookpr.com
 Alice Woodings / Paul McManus                                     Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893

 

 

 

 

 

About Tissue Regenix (www.tissueregenix.com)

 

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold that is not rejected by the patient's body and can
be used to repair diseased or damaged body structures. Current applications
address many crucial clinical needs in sports medicine, foot and ankle
injuries, and wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech
company specialises in regenerative medicine and is dedicated to developing
high-quality, innovative tissue scaffolds to enhance healing opportunities in
defects created by trauma and disease. CellRight's human tissue products may
be used in spine, trauma, general orthopaedic, dental and ophthalmological
surgical procedures.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBFMFTMTMMBLF



            Copyright 2019 Regulatory News Service, all rights reserved